302 related articles for article (PubMed ID: 25319413)
1. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
Bornancin F; Renner F; Touil R; Sic H; Kolb Y; Touil-Allaoui I; Rush JS; Smith PA; Bigaud M; Junker-Walker U; Burkhart C; Dawson J; Niwa S; Katopodis A; Nuesslein-Hildesheim B; Weckbecker G; Zenke G; Kinzel B; Traggiai E; Brenner D; Brüstle A; St Paul M; Zamurovic N; McCoy KD; Rolink A; Régnier CH; Mak TW; Ohashi PS; Patel DD; Calzascia T
J Immunol; 2015 Apr; 194(8):3723-34. PubMed ID: 25762782
[TBL] [Abstract][Full Text] [Related]
3. MALT1 protease: equilibrating immunity versus tolerance.
Bertossi A; Krappmann D
EMBO J; 2014 Dec; 33(23):2740-2. PubMed ID: 25361604
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
5. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination.
Mc Guire C; Wieghofer P; Elton L; Muylaert D; Prinz M; Beyaert R; van Loo G
J Immunol; 2013 Mar; 190(6):2896-903. PubMed ID: 23401595
[TBL] [Abstract][Full Text] [Related]
6. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
7. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
Front Immunol; 2019; 10():1898. PubMed ID: 31474984
[TBL] [Abstract][Full Text] [Related]
8. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
9. The paracaspase MALT1: biological function and potential for therapeutic inhibition.
Jaworski M; Thome M
Cell Mol Life Sci; 2016 Feb; 73(3):459-73. PubMed ID: 26507244
[TBL] [Abstract][Full Text] [Related]
10. The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Brüstle A; Brenner D; Knobbe CB; Lang PA; Virtanen C; Hershenfield BM; Reardon C; Lacher SM; Ruland J; Ohashi PS; Mak TW
J Clin Invest; 2012 Dec; 122(12):4698-709. PubMed ID: 23114599
[TBL] [Abstract][Full Text] [Related]
11. MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.
Yu JW; Hoffman S; Beal AM; Dykon A; Ringenberg MA; Hughes AC; Dare L; Anderson AD; Finger J; Kasparcova V; Rickard D; Berger SB; Ramanjulu J; Emery JG; Gough PJ; Bertin J; Foley KP
PLoS One; 2015; 10(5):e0127083. PubMed ID: 25965667
[TBL] [Abstract][Full Text] [Related]
12. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
13. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
14. MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression.
Pan D; Jiang C; Ma Z; Blonska M; You MJ; Lin X
Oncogene; 2016 Feb; 35(7):919-28. PubMed ID: 25982276
[TBL] [Abstract][Full Text] [Related]
15. MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.
Baens M; Bonsignore L; Somers R; Vanderheydt C; Weeks SD; Gunnarsson J; Nilsson E; Roth RG; Thome M; Marynen P
PLoS One; 2014; 9(8):e103774. PubMed ID: 25105596
[TBL] [Abstract][Full Text] [Related]
16. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface.
Cabalzar K; Pelzer C; Wolf A; Lenz G; Iwaszkiewicz J; Zoete V; Hailfinger S; Thome M
PLoS One; 2013; 8(8):e72051. PubMed ID: 23977204
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1.
Staal J; Driege Y; Bekaert T; Demeyer A; Muyllaert D; Van Damme P; Gevaert K; Beyaert R
EMBO J; 2011 May; 30(9):1742-52. PubMed ID: 21448133
[TBL] [Abstract][Full Text] [Related]
18. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
Gewies A; Gorka O; Bergmann H; Pechloff K; Petermann F; Jeltsch KM; Rudelius M; Kriegsmann M; Weichert W; Horsch M; Beckers J; Wurst W; Heikenwalder M; Korn T; Heissmeyer V; Ruland J
Cell Rep; 2014 Nov; 9(4):1292-305. PubMed ID: 25456129
[TBL] [Abstract][Full Text] [Related]
19. Unrestrained cleavage of Roquin-1 by MALT1 induces spontaneous T cell activation and the development of autoimmunity.
Schmidt H; Raj T; O'Neill TJ; Muschaweckh A; Giesert F; Negraschus A; Hoefig KP; Behrens G; Esser L; Baumann C; Feederle R; Plaza-Sirvent C; Geerlof A; Gewies A; Isay SE; Ruland J; Schmitz I; Wurst W; Korn T; Krappmann D; Heissmeyer V
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2309205120. PubMed ID: 37988467
[TBL] [Abstract][Full Text] [Related]
20. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
